Factors Associated with Cancer Treatment Resumption After ICU Stay in Patients with Solid Tumors

Overview

Journal Ann Intensive Care

Specialty Critical Care

Date 2024 Aug 31

PMID 39215851

Authors

Soraya Benguerfi

Ondine Messeant

Benoit Painvin

Christophe Camus

Adel Maamar

Arnaud Gacouin

Charles Ricordel

Jean Reignier

Emmanuel Canet

Julien Edeline

Jean-Marc Tadie

Affiliations

Soon will be listed here.

Abstract

Background: Post-intensive care syndrome could be responsible for inability to receive proper cancer treatment after ICU stay in patients with solid tumors (ST). Our purpose was to determine the factors associated with cancer treatment resumption and the impact of cancer treatment on the outcome of patients with ST after ICU stay.

Methods: We conducted a retrospective study including all patients with ST admitted to the ICU between 2014 and 2019 in a French University-affiliated Hospital.

Results: A total of 219 patients were included. Median SAPS II at ICU admission was 44.0 [IQR 32.8, 66.3]. Among the 136 patients who survived the ICU stay, 81 (59.6%) received cancer treatment after ICU discharge. There was an important increase in patients with poor performance status (PS) of 3 or 4 after ICU stay (16.2% at admission vs. 44.5% of patients who survived), with significant PS decline following the ICU stay (median difference - 1.5, 95% confidence interval [-1.5-1.0], p < 0.001). The difference between the PS after and before ICU stay (delta PS) was independently associated with inability to receive cancer treatment (Odds ratio OR 0.34, 95%CI 0.18-0.56, p value < 0.001) and with 1-year mortality in patients who survived at ICU discharge (Hazard ratio HR 1.76, 95%CI 1.34-2.31, p value < 0.001). PS before ICU stay (OR 3.73, 95%IC 2.01-7.82, p value < 0.001) and length of stay (OR 1.23, 95%CI 1.06-1.49, p value 0.018) were independently associated with poor PS after ICU stay. Survival rates at ICU discharge, at 1 and 3 years were 62.3% (n = 136), 27.3% (n = 59) and 17.1% (n = 37), respectively. The median survival for patients who resumed cancer treatment after ICU stay was 771 days (95%CI 376-1058), compared to 29 days (95%CI 15-49) for those who did not resume treatment (p < 0.001).

Conclusion: Delta PS, before and after ICU stay, stands out as a critical determinant of cancer treatment resumption and survival after ICU stay. Multidisciplinary intervention to improve the general condition of these patients, in ICU and after ICU stay, may improve access to cancer treatment and long-term survival.

References

Vigneron C, Charpentier J, Valade S, Alexandre J, Chelabi S, Palmieri L . Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment. Ann Intensive Care. 2021; 11(1):182. PMC: 8709803. DOI: 10.1186/s13613-021-00968-5. View

Kjaer E, Jensen J, Jakobsen K, Lelkaitis G, Wessel I, von Buchwald C . The Impact of Comorbidity on Survival in Patients With Head and Neck Squamous Cell Carcinoma: A Nationwide Case-Control Study Spanning 35 Years. Front Oncol. 2021; 10:617184. PMC: 7928275. DOI: 10.3389/fonc.2020.617184. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Darmon M, Bourmaud A, Georges Q, Soares M, Jeon K, Oeyen S . Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. Intensive Care Med. 2019; 45(7):977-987. DOI: 10.1007/s00134-019-05653-7. View

Bos M, Verburg I, Dumaij I, Stouthard J, Nortier J, Richel D . Intensive care admission of cancer patients: a comparative analysis. Cancer Med. 2015; 4(7):966-76. PMC: 4529335. DOI: 10.1002/cam4.430. View

Gonzalez F, Starka R, Ducros L, Bisbal M, Chow-Chine L, Servan L . Critically ill metastatic cancer patients returning home after unplanned ICU stay: an observational, multicentre retrospective study. Ann Intensive Care. 2023; 13(1):73. PMC: 10441975. DOI: 10.1186/s13613-023-01170-5. View

Borcoman E, Dupont A, Mariotte E, Doucet L, Joseph A, Chermak A . One-year survival in patients with solid tumours discharged alive from the intensive care unit after unplanned admission: A retrospective study. J Crit Care. 2020; 57:36-41. DOI: 10.1016/j.jcrc.2020.01.027. View

Rathi N, Haque S, Morales F, Kaul B, Ramirez R, Ovu S . Variability in triage practices for critically ill cancer patients: A randomized controlled trial. J Crit Care. 2019; 53:18-24. DOI: 10.1016/j.jcrc.2019.05.012. View

Needham D, Davidson J, Cohen H, Hopkins R, Weinert C, Wunsch H . Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med. 2011; 40(2):502-9. DOI: 10.1097/CCM.0b013e318232da75. View

10.

Tipping C, Harrold M, Holland A, Romero L, Nisbet T, Hodgson C . The effects of active mobilisation and rehabilitation in ICU on mortality and function: a systematic review. Intensive Care Med. 2016; 43(2):171-183. DOI: 10.1007/s00134-016-4612-0. View

11.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

12.

Elliott D, McKinley S, Alison J, Aitken L, King M, Leslie G . Health-related quality of life and physical recovery after a critical illness: a multi-centre randomised controlled trial of a home-based physical rehabilitation program. Crit Care. 2011; 15(3):R142. PMC: 3219014. DOI: 10.1186/cc10265. View

13.

Gautheret N, Bommier C, Mabrouki A, Souppart V, Bretaud A, Ghrenassia E . Feasibility and Safety of Active Physiotherapy in the Intensive Care Unit for Intubated Patients with Malignancy. J Rehabil Med. 2022; 55:jrm00299. PMC: 9926923. DOI: 10.2340/jrm.v54.736. View

14.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

15.

Gheerbrant H, Timsit J, Terzi N, Ruckly S, Laramas M, Giaj Levra M . Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013. BMC Cancer. 2021; 21(1):9. PMC: 7786972. DOI: 10.1186/s12885-020-07706-3. View

16.

Sogaard M, Thomsen R, Bossen K, Sorensen H, Norgaard M . The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013; 5(Suppl 1):3-29. PMC: 3820483. DOI: 10.2147/CLEP.S47150. View

17.

Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison D . Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study. JAMA Oncol. 2015; 1(8):1078-85. DOI: 10.1001/jamaoncol.2015.2855. View

18.

de Vries V, Muller M, Arbous M, Biemond B, Blijlevens N, Kusadasi N . Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. Crit Care Med. 2018; 47(2):e120-e128. PMC: 6336487. DOI: 10.1097/CCM.0000000000003526. View

19.

Ravasco P . Nutrition in Cancer Patients. J Clin Med. 2019; 8(8). PMC: 6723589. DOI: 10.3390/jcm8081211. View

20.

Kawakita D, Abdelaziz S, Chen Y, Rowe K, Snyder J, Fraser A . Adverse respiratory outcomes among head and neck cancer survivors in the Utah Cancer Survivors Study. Cancer. 2019; 126(4):879-885. PMC: 6992515. DOI: 10.1002/cncr.32617. View